Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2018
Improvement of Worsening in Diabetic Retinopathy Through 2 Years in a Randomized Trial
Susan B. Bressler, MD, FASRS
Updates from the Field
2017
PRN cycles of three monthly anti-VEGF injections in neovascular AMD: 12 and 24 months results.
Touka Banaee, MD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more